A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

NCT05254002 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1664

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions

DRUG: Finerenone (BAY94-8862 ) 10 mg
DRUG: Empagliflozin
DRUG: Empagliflozin Placebo
DRUG: Finerenone (BAY94-8862 ) 20 mg
DRUG: Finerenone Placebo

Sponsor

Bayer